arrow
D

David I. Quinn

AbbVie Inc.
H指数:77
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis

1b期研究:ABBV-744(一种新型选择性BET抑制剂)作为单药疗法在骨髓纤维化患者中的应用

2026-03-190
OAAI
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer

Ib期研究:恩扎卢胺联合维奈克拉用于转移性去势抵抗性前列腺癌患者的治疗

2025-11-290
OAAI
Efficacy of neratinib-based therapy in ERBB2-mutant lung adenocarcinomas: findings from 2 international phase 2 studies

奈拉替尼为基础疗法在ERBB2突变型肺腺癌中的疗效:2项国际II期研究的结果

2025-10-010
PRE
Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer

在去势抵抗性前列腺癌患者中,使用恩扎卢胺单药或联合镭-223治疗期间的免疫调节

CANCERS
IF4.4
2025-05-210
OA
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma

一项I/IB期、开放标签、剂量探索研究,旨在评估帕博利珠单抗联合伏立诺他治疗晚期前列腺癌、肾癌或尿路上皮癌患者的安全性、药效学和疗效。

2025-03-270
OAAI
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone- sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

3个月和7个月的前列腺特异性抗原水平可作为转移性激素敏感性前列腺癌总生存期的预后指标: SWOG S1216的结果,这是一项雄激素剥夺加Orteronel或比卡鲁胺的3期随机试验

2024-10-012
OA
First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

ABBV-969首次人体研究,该药物是一种双变量抗体药物偶联物(ADC),用于治疗转移性去势抵抗性前列腺癌(mCRPC)的患者(pts)。

2024-09-010
PRE
Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis

II期随机双盲试验,评估阿昔替尼(Axi)联合或不含PF 04518600(一种OX40抗体,PFOX)在PD1/PDL1抗体(IO)疗法(Tx)后用于转移性肾细胞癌(mRCC)的最终分析。

2024-09-010
PRE
A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option

一项随机、II期临床试验,旨在评估在局部晚期或转移性移行细胞尿路上皮癌患者中,当顺铂为基础的治疗不可行时,注射用埃罗替尼(eribulin mesylate)联合阿替利珠单抗(atezolizumab)与单独使用阿替利珠单抗(atezolizumab)在安全性及有效性方面的比较。

2024-09-010
PRE
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial

在接受第二线帕博利珠单抗治疗的尿路上皮癌患者中,先前化疗对疗效的影响:KEYNOTE-045 III期试验的探索性分析

2024-08-220
PREAI
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel
2024-02-290
PRE
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
2024-02-016
OA
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
2024-01-018
OA
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
2023-11-030
OAAI
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

来纳替尼对HER2-mutant晚期胆道癌患者的抗肿瘤活性

2023-02-0631
OAAI